TRANSGENE SA (TNG.PA) Stock Overview
Europe - EPA:TNG - FR0005175080 - Common Stock
TNG.PA Key Statistics, Chart & Performance
The current stock price of TNG.PA is 1.313 EUR. In the past month the price increased by 19.13%. In the past year, price increased by 51.05%.
TNG.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 21.37 | 343.95B | ||
| AMG.DE | AMGEN INC | 13.33 | 134.59B | ||
| 1GILD.MI | GILEAD SCIENCES INC | 15.9 | 131.38B | ||
| GIS.DE | GILEAD SCIENCES INC | 15.11 | 124.90B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 24.66 | 92.11B | ||
| 1AE.DE | ARGENX SE | 95.94 | 43.89B | ||
| ARGX.BR | ARGENX SE | 96.77 | 44.27B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.76B | ||
| IDP.DE | BIOGEN INC | 9.31 | 18.79B | ||
| 1MRNA.MI | MODERNA INC | N/A | 8.99B | ||
| 0QF.DE | MODERNA INC | N/A | 8.44B | ||
| 1EXEL.MI | EXELIXIS INC | 17.15 | 8.26B |
Related stock screener links
About TNG.PA
Company Profile
Transgene SA is a biotechnology company that focuses on designing and developing targeted immunotherapies for the treatment of cancer. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 147 full-time employees. The firm designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The firm has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The firm also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The firm's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The firm's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).
Company Info
TRANSGENE SA
400 Boulevard Gonthier d'Andernach, Parc d'Innovation - CS80166, Cedex
Illkirch-Graffenstaden GRAND EST FR
Employees: 144
Phone: 33388279100
TRANSGENE SA / TNG.PA FAQ
What does TRANSGENE SA do?
Transgene SA is a biotechnology company that focuses on designing and developing targeted immunotherapies for the treatment of cancer. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 147 full-time employees. The firm designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The firm has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The firm also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The firm's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The firm's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).
What is the current price of TNG stock?
The current stock price of TNG.PA is 1.313 EUR. The price decreased by -4.16% in the last trading session.
What is the dividend status of TRANSGENE SA?
TNG.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of TNG stock?
TNG.PA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for TNG.PA stock?
7 analysts have analysed TNG.PA and the average price target is 1.8 EUR. This implies a price increase of 37.25% is expected in the next year compared to the current price of 1.313.
Can you provide the ownership details for TNG stock?
You can find the ownership structure of TRANSGENE SA (TNG.PA) on the Ownership tab.
TNG.PA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to TNG.PA. When comparing the yearly performance of all stocks, TNG.PA is one of the better performing stocks in the market, outperforming 93.83% of all stocks.
TNG.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to TNG.PA. TNG.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
TNG.PA Financial Highlights
Over the last trailing twelve months TNG.PA reported a non-GAAP Earnings per Share(EPS) of -0.29. The EPS decreased by -31.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -82.88% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
TNG.PA Forecast & Estimates
7 analysts have analysed TNG.PA and the average price target is 1.8 EUR. This implies a price increase of 37.25% is expected in the next year compared to the current price of 1.313.
For the next year, analysts expect an EPS growth of 125.93% and a revenue growth -31.56% for TNG.PA